Clinical Efficacy of Immunotherapy with Pd-1/Pd-L1 Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer
Download as PDF
Author(s)
Shengjie Yang, Xiao Ma, Wenjie Zhang, Qing Chen, Qisen Guo
Corresponding Author
Qisen Guo
Abstract
Immunotherapeutics like programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors effectively control non-small cell lung cancer (NSCLC) in clinical trials. This study assessed the association of different clinicopathological parameters with the treatment effectiveness and prognosis of NSCLC patients in a real-world setting. Seventy-five patients received PD-1/PD-L1 inhibitors and were evaluated for overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Eighteen patients reached a partial response (PR) (24%), 45 had stable disease (SD) (60%), and 12 had progressive disease (PD) (16%), resulting in an ORR of 24% and a DCR of 84%. For the 11 PD-L1-positive patients, the ORR was 36.36%. Moreover, 16 patients (21%) had died and 34 (45%) had SD at the last follow-up, leading to a PFS of 8.3 months (95% confidence interval (CI): 6.8–12.2 months) and an OS of 17 months (95%CI: 16.7–26.5 months). The Eastern Cooperative Oncology Group (ECOG) score was associated with the treatment-related PFS and OS. The factors associated with the prognosis were ECOG score, line of immunotherapy, tobacco smoking, PD-L1 positivity, and tumor pathology. This study confirmed the clinical effectiveness of PD-1/PD-L1 inhibitor immunotherapy against advanced NSCLC.
Keywords
Lung cancer, Pd-1, Pd-l1, Pd-1/pd-l1 inhibitors, Effectiveness, Survival
Acknowledgments
None
References
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, Vol. 68, No.6, pp. 394-424, 2018.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, Vol. 66, No.2, pp. 115-132, 2016.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, Vol. 70, No. 1, pp. 7-30, 2020.
[4] Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med, Vol. 41, No. 1, pp. 1-24, 2020.
[5] Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med, Vol. 376, No. 22, pp. 2109-2121, 2017.
[6] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, Vol. 377, No.20, pp. 1919-1929, 2017.
[7] Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med, Vol. 378, No. 21, pp. 1976-1986, 2018.
[8] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med, Vol. 382, No.1, pp. 41-50, 2020.
[9] de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, Vol. 382, No. 6, pp. 503-513, 2020.
[10] Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, Vol. 16, No. 2, pp. 141-151, 2015.
[11] Zeng L, Xiao L, Jiang W, et al. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung Cancer, No.141, pp. 82-88, 2020.
[12] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, Vol. 373, No. 2, PP. 123-135, 2015.
[13] Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, Vol. 34, No. 25, pp. 2980-2987, 2016.
[14] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, Vol. 387, No. 10027, pp. 1540-1550, 2016.
[15] Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol, Vol. 17, No.11, pp. 1497-1508, 2016.
[16] Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, Vol. 393, No.10183, pp. 1819-1830, 2019.
[17] Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, Vol. 375, No.19, pp. 1823-1833, 2016.
[18] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, Vol. 11, No.1, pp. 39-51, 206.
[19] Huemer F, Lang D, Westphal T, et al. Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. J Clin Med, Vol. 8, No.7, 2019.
[20] Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol, Vol. 13, No.8, pp. 790-801, 2012.
[21] Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog, Vol. 18, No.6, pp. 573-583, 2013.
[22] Elias R, Morales J, Presley C. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr Oncol Rep, Vol. 19, No.9, pp.62, 2017.
[23] Ferrara R, Mezquita L, Auclin E, et al. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? Cancer Treat Rev, No.60, pp.60-68, 2017.
[24] Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol, Vol. 14, No.3, pp. 547-552, 2019.
[25] Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol, No.8, pp. 561, 2017.
[26] Syn NL, Teng MWL, Mok TSK, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol, Vol. 18, No.12, pp. e731-e741, 2017.
[27] Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol, No. 23, pp. 32-38, 2015.
[28] Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers, Vol. 5, No, 1, pp. 5, 2019.
[29] Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol, Vol. 23, No. 25, pp. 6207-6219, 2005.
[30] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, Vol. 12, No. 4, pp. 252-264, 2012.
[31] Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, Vol. 387, No. 10030, pp. 1837-1846, 2016.
[32] Horn L, Spigel DR, Vokes EE, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol, Vol. 35, No. 35, pp. 3924-3933, 2017.